Educational Webinars

In partnership with The ALS Association, NEALS offers live webinars for people living with ALS, caregivers, and the broader ALS community.

Webinar topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments. Our webinars also offer participants the opportunity to ask questions directly of the experts running clinical trials and conducting research activities.

March 28, 2023 / 12:30 pm-1:30 pm

NEALS Webinar: An Update on Tofersen

Please join us for a webinar update on tofersen moderated by NEALS Co-Chair Dr. Jinsy Andrews. Dr. Timothy Miller will provide background on tofersen and updates from the March 22nd FDA Advisory Committee Meeting. Holly Fernandez Lynch,…

March 20, 2023 / 12:00 pm-1:00 pm

Phase 2 Trial of AP-101 in SOD1 and Sporadic ALS

Dr. Angela Genge (Montreal Neurological Institute-Hospital) discusses the research behind AP-101 and provides an overview of the trial and what study participation involves. The phase 2 trial of AP-101 is currently enrolling…

January 18, 2023 / 12:00 pm-1:00 pm

ALSUntangled – Vitamins and Supplements in ALS

In this webinar, Dr. Bedlack will review ALSUntangled, including how patients and families can use it to make more informed decisions about vitamins and supplements. He will show how he guides patients at Duke who want to…

December 8, 2022 / 1:00 pm-2:00 pm

Update on COURAGE-ALS: A Phase 3 Trial of Reldesemtiv, a Muscle Directed Drug

Speaker: Dr. Jeremy Shefner (Barrow Neurological Institute)An update on the currently enrolling COURAGE-ALS trial will be provided. This will include results of the first interim analysis, a review of the novel mechanism of action for…

November 28, 2022 / 1:00 pm-2:00 pm

Trials of the Future: Remote Monitoring

Speakers: Dr. Christina Fournier (Emory University), Dr. Andrew Geronimo (Penn State Health), and Dr. Eufrosina Young (SUNY Upstate)

Join us for a webinar on remote monitoring for clinical care moderated by NEALS Co-Chair Dr.…

November 9, 2022 / 4:00 pm-5:00 pm

ALS Himalaya trial: a global, double-blind, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR443820, a RIPK1 inhibitor, in adult participants with ALS

Speakers: Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at MGH) and Dr. Nazem Atassi (Sanofi)The webinar discussion will include the mechanism of action of RIPK1 inhibition, efficacy in animal models, results from Phase 1…